References:
1. Prete A, Bancos I (2021) Glucocorticoid induced adrenal
insufficiency. BMJ 374:n1380.
2. Xie M, Yang A, Ma J, Wu M, Xu H, Wu K, Jin Y, et al (2019) Akt2
mediates glucocorticoid resistance in lymphoid malignancies through
FoxO3a/Bim axis and serves as a direct target for resistance reversal.Cell Death Dis 9:1013.
3. Gallagher KM, Roderick JE, Tan SH, Tan TK, Murphy L, Yu J, Li R, et
al (2020) ESRRB regulates glucocorticoid gene expression in mice and
patients with acute lymphoblastic leukemia. Blood Adv4:3154-3168.
4. Dehghan-Nayeri N, Rezaei-Tavirani M, Omrani MD, Gharehbaghian A,
Goudarzi Pour K, Eshghi P. ( 2017) Identification of potential
predictive markers of dexamethasone resistance in childhood acute
lymphoblastic leukemia. J Cell Commun Signal 11:137-145.
5. Xagorari M, Marmarinos A, Kossiva L, Baka M, Doganis D, Servitzoglou
M, Tsolia M, et al (2021) Overexpression of the GR Riborepressor LncRNA
GAS5 Results in Poor Treatment Response and Early Relapse in Childhood
B-ALL. Cancers (Basel) 13 :6064.
6. Rinaldi L, Fettweis G, Kim S, Garcia DA, Fujiwara S, Johnson TA,
Tettey TT, et al (2022) The glucocorticoid receptor associates with the
cohesin loader NIPBL to promote long-range gene regulation. Sci
Adv 8: eabj8360.
7. Diaz-Jimenez D, Petrillo MG, Busada JT, Hermoso MA, Cidlowski
JA(2020)Glucocorticoids mobilize macrophages by transcriptionally
up-regulating the exopeptidase DPP4. J Biol Chem 295:3213-3227.
8. Bai M, Chen M, Zeng Q, Lu S, Li P, Ma Z, Lin N, et
al(2022)Up-regulation of hepatic CD36 by increased
corticosterone/cortisol levels via GR leads to lipid accumulation in
liver and hypertriglyceridaemia during pregnancy. Br J Pharmacol179:4440-4456.
9. Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, Campbell
CT, et al(2016)DOT1L as a therapeutic target for the treatment of
DNMT3A-mutant acute myeloid leukemia. BLOOD 128:971-981.
10. Farooq Z, Banday S, Pandita TK, Altaf M(2016)The many faces of
histone H3K79 methylation. Mutat Res Rev Mutat Res 768:
46-52.
11. Min J, Feng Q, Li Z, Zhang Y, Xu RM(2003)Structure of the
catalytic domain of human DOT1L, a non-SET domain nucleosomal histone
methyltransferase. CELL 112:711-723.
12. Duan Y, Wu X, Zhao Q, Gao J, Huo D, Liu X, Ye Z, et al(2016)DOT1L
promotes angiogenesis through cooperative regulation of VEGFR2 with
ETS-1. Oncotarget 7: 69674-69687.
13. Kim W, Kim R, Park G, Park JW, Kim JE(2012)Deficiency of H3K79
histone methyltransferase Dot1-like protein (DOT1L) inhibits cell
proliferation. J BIOL CHEM 287: 5588-5599.
14. Zhang L, Deng L, Chen F, Yao Y, Wu B, Wei L, Mo Q, et
al(2014)Inhibition of histone H3K79 methylation selectively inhibits
proliferation, self-renewal and metastatic potential of breast cancer,Oncotarget 5: 10665-10677.
15. Zhang X, Liu D, Li M, Cao C, Wan D, Xi B, Li W, et
al(2017)Prognostic and therapeutic value of disruptor of telomeric
silencing-1-like (DOT1L) expression in patients with ovarian cancer.
J Hematol Oncol 10: 29.
16. Wong M, Tee AEL, Milazzo G, Bell JL, Poulos RC, Atmadibrata B, Sun
Y, et al(2017)The histone methyltransferase DOT1L promotes
neuroblastoma by regulating gene transcription. Cancer Res77:2522-2533.
17. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, et
al(2005)hDOT1L links histone methylation to leukemogenesis.CELL 121: 167-178.
18. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song
J, Johnston LD, et al (2011) Selective killing of mixed lineage
leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer
Cell 20: 53-65.
19. Klaus CR, Iwanowicz D, Johnston D, Campbell CA, Smith JJ, Moyer MP,
Copeland RA, et al(2014)DOT1L inhibitor EPZ-5676 displays synergistic
antiproliferative activity in combination with standard of care drugs
and hypomethylating agents in MLL-rearranged leukemia cells. J
Pharmacol Exp Ther 350:646-656.
20. Waters NJ(2017)Preclinical Pharmacokinetics and Pharmacodynamics
of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl
Methionine Competitive Inhibitor of DOT1L. Eur J Drug Metab
Pharmacokinet 42:891-901.
21. Malyukova A, Brown S, Papa R, O’Brien R, Giles J, Trahair TN, Dalla
Pozza L, et al(2013) FBXW7 regulates glucocorticoid response in T-cell
acute lymphoblastic leukaemia by targeting the glucocorticoid receptor
for degradation. Leukemia 27: 1053-1062.
22. Pires-Luís AS, Vieira-Coimbra M, Vieira FQ, Costa-Pinheiro P,
Silva-Santos R, Dias PC, Antunes L, et al(2015)Expression of histone
methyltransferases as novel biomarkers for renal cell tumor diagnosis
and prognostication. Epigenetics 10: 1033-1043.
23. Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang HE,
et al(2013)Global chromatin profiling reveals NSD2 mutations in
pediatric acute lymphoblastic leukemia. Nat Genet 45: 1386-1391.
24. Morera L, Lübbert M, Jung M(2016)Targeting histone
methyltransferases and demethylases in clinical trials for cancer
therapy. Clin Epigenetics 8: 57.
25. Mohammad HP, Barbash O, Creasy CL(2019)Targeting epigenetic
modifications in cancer therapy: erasing the roadmap to cancer.Nat Med 25: 403-418.
26. Kim W, Choi M, Kim JE(2014)The histone methyltransferase
Dot1/DOT1L as a critical regulator of the cell cycle. Cell Cycle13: 726-738.
27. Pogribny IP, Ross SA, Tryndyak VP, Pogribna M, Poirier LA, Karpinets
TV(2006)Histone H3 lysine 9 and H4 lysine 20 trimethylation and the
expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in
hepatocarcinogenesis induced by methyl deficiency in rats.Carcinogenesis 27: 1180-1186.
28. Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A,
Tamburrano G, et al (2014) Epigenetic-related gene expression profile
in medullary thyroid cancer revealed the overexpression of the histone
methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol Cell
Endocrinol 392: 8-13.
29. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng
Z, et al(2011)MLL-rearranged leukemia is dependent on aberrant H3K79
methylation by DOT1L. Cancer Cell 20: 66-78.
30. Qu Y, Liu L, Wang J, Xi W, Xia Y, Bai Q, Xiong Y, et al(2016)Dot1l
expression predicts adverse postoperative prognosis of patients with
clear-cell renal cell carcinoma. Oncotarget 7: 84775-84784.
31. Bindreither D, Ecker S, Gschirr B, Kofler A, Kofler R, Rainer
J(2014)The synthetic glucocorticoids prednisolone and dexamethasone
regulate the same genes in acute lymphoblastic leukemia cells. BMC
Genomics 15: 662.
32. Dehghan-Nayeri N, Rezaei-Tavirani M, Omrani MD, Gharehbaghian A,
Goudarzi Pour K, Eshghi P(2016)Identification of potential predictive
markers of dexamethasone resistance in childhood acute lymphoblastic
leukemia. J Cell Commun Signal 11:137-145.
33. Huang Y, Zhou J, Huang Y, He J, Wang Y, Yang C, Liu D, et
al(2016)SARI, a novel target gene of glucocorticoid receptor, plays an
important role in dexamethasone-mediated killing of B lymphoma cells.Cancer Lett 373:57-66.
34. Rhen T, Cidlowski JA(2005)Antiinflammatory action of
glucocorticoids–new mechanisms for old drugs. N Engl J Med353: 1711-1723.
35. Zhou P, Huang G, Zhao Y, Zhong D, Xu Z, Zeng Y, Zhang Y, et
al(2014) MicroRNA-363-mediated downregulation of S1PR1 suppresses the
proliferation of hepatocellular carcinoma cells. Cell Signal 26:
1347-1354.
36. Wu Y, Ni Z, Yan X, Dai X, Hu C, Zheng Y, He F, et
al(2016)Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the
sensitivity of cervical cancer cells to pirarubicin. Autophagy12: 1105-1117.
37. Subramaniam D, Natarajan G, Ramalingam S, Ramachandran I, May R,
Queimado L, Houchen CW, et al(2008)Translation inhibition during cell
cycle arrest and apoptosis: Mcl-1 is a novel target for RNA binding
protein CUGBP2. Am J Physiol Gastrointest Liver Physiol294:G1025-1032.
38. Liu C, Yang Q, Zhu Q, Lu X, Li M, Hou T, Li Z, et al(2020)CBP
mediated DOT1L acetylation confers DOT1L stability and promotes cancer
metastasis. Theranostics 10: 1758-1776.
39. Korać P, Dotlić S, Matulić M, Zajc Petranović M, Dominis
M(2017)Role of MYC in B Cell Lymphomagenesis. Genes(Basel) 8:115.
40. Wang J, Bi X, Li P, Xia Z, Huang H, Jiang W, Zhang Y, et
al(2017)Overexpression of MYC and BCL2 Predicts Poor Prognosis in
Patients with Extranodal NK/T-cell Lymphoma, Nasal Type. J Cancer8: 793-800.